letrozole has been researched along with Anovulation in 28 studies
Anovulation: Suspension or cessation of OVULATION in animals or humans with follicle-containing ovaries (OVARIAN FOLLICLE). Depending on the etiology, OVULATION may be induced with appropriate therapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Letrozole appears to improve live birth rates and pregnancy rates in infertile women with anovulatory PCOS, compared to SERMs, when used for ovulation induction, followed by intercourse." | 9.22 | Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. ( Farquhar, C; Franik, S; Kiesel, L; Kremer, JA; Le, QK, 2022) |
| "To compare the clinical outcomes of letrozole and laparoscopic ovarian drilling (LOD) in patients with clomiphene-citrate-resistant polycystic ovary syndrome (PCOS)." | 9.15 | Reproductive outcome after letrozole versus laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome. ( Abdellah, MS, 2011) |
| "To evaluate the outcome of long letrozole therapy for induction of ovulation in patients with clomiphene-resistant polycystic ovary syndrome (PCOS)." | 9.14 | Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol. ( Badawy, A; Eid, M; Mosbah, A; Tharwat, A, 2009) |
| "This review focuses on the efficacy of letrozole stimulated frozen-thawed embryo transfer (FET) compared to hormone replacement therapy (HRT) FET in women with polycystic ovarian syndrome (PCOS) and/or oligo-anovulation." | 5.41 | The future of frozen-thawed embryo transfer in hormone replacement therapy cycles. ( Asserhøj, LL; Dam, TV; Løssl, K; Pinborg, A; Spangmose, AL, 2023) |
| "Letrozole is a potent, nonsteroidal, aromatase inhibitor, originally used for postmenopausal breast cancer therapy, at present its only registered indication." | 5.37 | Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. ( Casper, RF; Mitwally, MF, 2011) |
| " Additionally, novel cosmetic techniques like electrolysis, laser and use of topically applied eflornithine to tackle the most distressing feature of facial hirsutism associated with PCOS, non-pharmacological therapy like acupuncture and the role of herbal medicine in PCOS management have also been discussed." | 5.22 | Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. ( Ali, T; Amin, F; Ara, R; Bader, GN; Kareem, O; Malik, A; Mir, SA; Rashid, R, 2022) |
| "Letrozole appears to improve live birth rates and pregnancy rates in infertile women with anovulatory PCOS, compared to SERMs, when used for ovulation induction, followed by intercourse." | 5.22 | Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. ( Farquhar, C; Franik, S; Kiesel, L; Kremer, JA; Le, QK, 2022) |
| "To compare the clinical outcomes of letrozole and laparoscopic ovarian drilling (LOD) in patients with clomiphene-citrate-resistant polycystic ovary syndrome (PCOS)." | 5.15 | Reproductive outcome after letrozole versus laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome. ( Abdellah, MS, 2011) |
| "To evaluate the outcome of long letrozole therapy for induction of ovulation in patients with clomiphene-resistant polycystic ovary syndrome (PCOS)." | 5.14 | Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol. ( Badawy, A; Eid, M; Mosbah, A; Tharwat, A, 2009) |
| "To compare the effectiveness of letrozole and clomiphene citrate (CC) in ovulatory patients with borderline male factor infertility, early stage endometriosis, and unexplained infertility." | 5.12 | Letrozole vs. clomiphene citrate in patients with ovulatory infertility. ( Ayoğlu, F; Barut, A; Bayar, U; Kaya, E; Ozcan, O; Tanriverdi, HA, 2006) |
| " With letrozole treatment in the same patients with PCOS, ovulation occurred in 9 of 12 cycles (75%) and pregnancy was achieved in 3 patients (25%)." | 5.09 | Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. ( Casper, RF; Mitwally, MF, 2001) |
| "Randomised controlled trials comparing eight ovulation induction treatments in women with WHO group II anovulation: clomiphene, letrozole, metformin, clomiphene and metformin combined, tamoxifen, gonadotropins, laparoscopic ovarian drilling, and placebo or no treatment." | 4.95 | Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis ( Bhattacharya, S; Costello, MF; Johnson, NP; Kim, BV; Legro, RS; Mol, BW; Ng, EH; Norman, RJ; van Wely, M; Wang, R; Zhang, H, 2017) |
| "Polycystic ovarian syndrome is the major cause of anovulation and is generally associated with obesity." | 2.48 | Evaluation and treatment of anovulatory and unexplained infertility. ( Bates, GW; Propst, AM, 2012) |
| "Letrozole has fewer side effects, and a shorter half-life than clomiphene citrate, and no demonstrable effect upon the receptivity of the endometrium." | 2.46 | Letrozole for ovulation induction and controlled ovarian hyperstimulation. ( Pritts, EA, 2010) |
| "Acne is an off-label use of some COCs." | 1.72 | Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022) |
| "Treatment with letrozole + rFSH was more efficacious than letrozole alone for pregnancy in the IUI program; however, the effect of 5." | 1.42 | A comparison of the efficacy of two doses of letrozole alone or with continuous recombinant follicle-stimulating hormone for ovulation induction in anovulatory women. ( Wang, HY; Zheng, PS, 2015) |
| "Letrozole is a potent, nonsteroidal, aromatase inhibitor, originally used for postmenopausal breast cancer therapy, at present its only registered indication." | 1.37 | Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. ( Casper, RF; Mitwally, MF, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (17.86) | 29.6817 |
| 2010's | 17 (60.71) | 24.3611 |
| 2020's | 6 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Rashid, R | 1 |
| Mir, SA | 1 |
| Kareem, O | 1 |
| Ali, T | 1 |
| Ara, R | 1 |
| Malik, A | 1 |
| Amin, F | 1 |
| Bader, GN | 1 |
| Wilkinson, LD | 1 |
| Brady, PH | 1 |
| Gin, GT | 1 |
| Rosenblum, E | 1 |
| Franik, S | 1 |
| Le, QK | 1 |
| Kremer, JA | 1 |
| Kiesel, L | 1 |
| Farquhar, C | 1 |
| Bhattarai, P | 1 |
| Rijal, S | 1 |
| Bhattarai, JP | 1 |
| Cho, DH | 1 |
| Han, SK | 1 |
| Løssl, K | 2 |
| Spangmose, AL | 1 |
| Asserhøj, LL | 1 |
| Dam, TV | 1 |
| Pinborg, A | 1 |
| Dahlberg, ES | 1 |
| Andersen, D | 1 |
| Andersson, PS | 1 |
| Birch, K | 1 |
| Colmon, L | 1 |
| Holt, MD | 1 |
| Ingerslev, K | 1 |
| Kirkegaard, K | 1 |
| Poulsen, LC | 1 |
| Wissing, ML | 1 |
| Yde, M | 1 |
| Bülow, NS | 1 |
| Carvalho, MJ | 1 |
| Subtil, S | 1 |
| Rodrigues, Â | 1 |
| Oliveira, J | 1 |
| Figueiredo-Dias, M | 1 |
| Check, JH | 1 |
| Liss, JR | 1 |
| Check, D | 1 |
| Winiczenko, R | 1 |
| Górnicki, K | 1 |
| Kaleta, A | 1 |
| Janaszek-Mańkowska, M | 1 |
| Khan, ZA | 1 |
| Singh, C | 1 |
| Khan, T | 1 |
| Ganguly, M | 1 |
| Bradsher, C | 1 |
| Goodwin, P | 1 |
| Petty, JT | 1 |
| Sandau, C | 1 |
| Bove, DG | 1 |
| Marsaa, K | 1 |
| Bekkelund, CS | 1 |
| Lindholm, MG | 1 |
| Salazar, J | 1 |
| Bermúdez, V | 1 |
| Olivar, LC | 1 |
| Torres, W | 1 |
| Palmar, J | 1 |
| Añez, R | 1 |
| Ordoñez, MG | 1 |
| Rivas, JR | 1 |
| Martínez, MS | 1 |
| Hernández, JD | 1 |
| Graterol, M | 1 |
| Rojas, J | 1 |
| Mubarak, Z | 1 |
| Humaira, A | 1 |
| Gani, BA | 1 |
| Muchlisin, ZA | 1 |
| Gremillet, C | 1 |
| Jakobsson, JG | 1 |
| Gomila, A | 1 |
| Shaw, E | 1 |
| Carratalà, J | 1 |
| Leibovici, L | 1 |
| Tebé, C | 1 |
| Wiegand, I | 1 |
| Vallejo-Torres, L | 1 |
| Vigo, JM | 1 |
| Morris, S | 1 |
| Stoddart, M | 1 |
| Grier, S | 1 |
| Vank, C | 1 |
| Cuperus, N | 1 |
| Van den Heuvel, L | 1 |
| Eliakim-Raz, N | 1 |
| Vuong, C | 1 |
| MacGowan, A | 1 |
| Addy, I | 1 |
| Pujol, M | 1 |
| Cobb, A | 1 |
| Rieger, E | 1 |
| Bell, J | 1 |
| Mallik, S | 1 |
| Zhao, Z | 1 |
| Szécsényi, Á | 1 |
| Li, G | 1 |
| Gascon, J | 1 |
| Pidko, EA | 1 |
| Zhang, GR | 1 |
| Wolker, T | 1 |
| Sandbeck, DJS | 1 |
| Munoz, M | 1 |
| Mayrhofer, KJJ | 1 |
| Cherevko, S | 1 |
| Etzold, BJM | 1 |
| Lukashuk, L | 1 |
| Yigit, N | 1 |
| Rameshan, R | 1 |
| Kolar, E | 1 |
| Teschner, D | 1 |
| Hävecker, M | 1 |
| Knop-Gericke, A | 1 |
| Schlögl, R | 1 |
| Föttinger, K | 1 |
| Rupprechter, G | 1 |
| Franconieri, F | 1 |
| Deshayes, S | 1 |
| de Boysson, H | 1 |
| Trad, S | 1 |
| Martin Silva, N | 1 |
| Terrier, B | 1 |
| Bienvenu, B | 1 |
| Galateau-Sallé, F | 1 |
| Emile, JF | 1 |
| Johnson, AC | 1 |
| Aouba, A | 1 |
| Vogt, TJ | 1 |
| Gevensleben, H | 1 |
| Dietrich, J | 1 |
| Kristiansen, G | 1 |
| Bootz, F | 1 |
| Landsberg, J | 1 |
| Goltz, D | 1 |
| Dietrich, D | 1 |
| Idorn, M | 1 |
| Skadborg, SK | 1 |
| Kellermann, L | 1 |
| Halldórsdóttir, HR | 1 |
| Holmen Olofsson, G | 1 |
| Met, Ö | 1 |
| Thor Straten, P | 1 |
| Johnson, LE | 1 |
| Brockstedt, D | 1 |
| Leong, M | 1 |
| Lauer, P | 1 |
| Theisen, E | 1 |
| Sauer, JD | 1 |
| McNeel, DG | 1 |
| Morandi, F | 1 |
| Marimpietri, D | 1 |
| Horenstein, AL | 1 |
| Bolzoni, M | 1 |
| Toscani, D | 1 |
| Costa, F | 1 |
| Castella, B | 1 |
| Faini, AC | 1 |
| Massaia, M | 1 |
| Pistoia, V | 1 |
| Giuliani, N | 1 |
| Malavasi, F | 1 |
| Qiu, J | 1 |
| Peng, S | 1 |
| Yang, A | 1 |
| Ma, Y | 1 |
| Han, L | 1 |
| Cheng, MA | 1 |
| Farmer, E | 1 |
| Hung, CF | 1 |
| Wu, TC | 1 |
| Modak, S | 1 |
| Le Luduec, JB | 1 |
| Cheung, IY | 1 |
| Goldman, DA | 1 |
| Ostrovnaya, I | 1 |
| Doubrovina, E | 1 |
| Basu, E | 1 |
| Kushner, BH | 1 |
| Kramer, K | 1 |
| Roberts, SS | 1 |
| O'Reilly, RJ | 1 |
| Cheung, NV | 1 |
| Hsu, KC | 1 |
| Salgarello, T | 1 |
| Giudiceandrea, A | 1 |
| Calandriello, L | 1 |
| Marangoni, D | 1 |
| Colotto, A | 1 |
| Caporossi, A | 1 |
| Falsini, B | 1 |
| Lefrançois, P | 1 |
| Xie, P | 1 |
| Wang, L | 2 |
| Tetzlaff, MT | 1 |
| Moreau, L | 1 |
| Watters, AK | 1 |
| Netchiporouk, E | 1 |
| Provost, N | 1 |
| Gilbert, M | 1 |
| Ni, X | 1 |
| Sasseville, D | 1 |
| Wheeler, DA | 1 |
| Duvic, M | 1 |
| Litvinov, IV | 1 |
| O'Connor, BJ | 1 |
| Fryda, NJ | 1 |
| Ranglack, DH | 1 |
| Yang, Y | 2 |
| Yang, J | 1 |
| Zhang, X | 2 |
| Grün, AL | 1 |
| Emmerling, C | 1 |
| Aumeeruddy-Elalfi, Z | 1 |
| Ismaël, IS | 1 |
| Hosenally, M | 1 |
| Zengin, G | 1 |
| Mahomoodally, MF | 1 |
| Dotsenko, A | 1 |
| Gusakov, A | 1 |
| Rozhkova, A | 1 |
| Sinitsyna, O | 1 |
| Shashkov, I | 1 |
| Sinitsyn, A | 1 |
| Hong, CE | 1 |
| Kim, JU | 1 |
| Lee, JW | 1 |
| Lee, SW | 1 |
| Jo, IH | 1 |
| Pandiyarajan, S | 1 |
| Premasudha, P | 1 |
| Kadirvelu, K | 1 |
| Wang, B | 1 |
| Luo, L | 1 |
| Wang, D | 1 |
| Ding, R | 1 |
| Hong, J | 1 |
| Caviezel, D | 1 |
| Maissen, S | 1 |
| Niess, JH | 1 |
| Kiss, C | 1 |
| Hruz, P | 1 |
| Pockes, S | 1 |
| Wifling, D | 1 |
| Keller, M | 1 |
| Buschauer, A | 1 |
| Elz, S | 1 |
| Santos, AF | 1 |
| Ferreira, IP | 1 |
| Pinheiro, CB | 1 |
| Santos, VG | 1 |
| Lopes, MTP | 1 |
| Teixeira, LR | 1 |
| Rocha, WR | 1 |
| Rodrigues, GLS | 1 |
| Beraldo, H | 1 |
| Lohar, S | 1 |
| Dhara, K | 1 |
| Roy, P | 1 |
| Sinha Babu, SP | 1 |
| Chattopadhyay, P | 1 |
| Sukwong, P | 1 |
| Sunwoo, IY | 1 |
| Lee, MJ | 1 |
| Ra, CH | 1 |
| Jeong, GT | 1 |
| Kim, SK | 2 |
| Huvinen, E | 1 |
| Eriksson, JG | 1 |
| Stach-Lempinen, B | 1 |
| Tiitinen, A | 1 |
| Koivusalo, SB | 1 |
| Malhotra, M | 1 |
| Suresh, S | 1 |
| Garg, A | 1 |
| Wei, L | 1 |
| Jiang, Y | 2 |
| Zhou, W | 1 |
| Liu, S | 1 |
| Liu, Y | 1 |
| Rausch-Fan, X | 1 |
| Liu, Z | 1 |
| Marques, WL | 1 |
| van der Woude, LN | 1 |
| Luttik, MAH | 1 |
| van den Broek, M | 1 |
| Nijenhuis, JM | 1 |
| Pronk, JT | 1 |
| van Maris, AJA | 1 |
| Mans, R | 1 |
| Gombert, AK | 1 |
| Xu, A | 1 |
| Sun, J | 1 |
| Li, J | 1 |
| Chen, W | 2 |
| Zheng, R | 1 |
| Han, Z | 1 |
| Ji, L | 1 |
| Shen, WQ | 1 |
| Bao, LP | 1 |
| Hu, SF | 1 |
| Gao, XJ | 1 |
| Xie, YP | 1 |
| Gao, XF | 1 |
| Huang, WH | 1 |
| Lu, X | 1 |
| Gostin, PF | 1 |
| Addison, O | 1 |
| Morrell, AP | 1 |
| Zhang, Y | 2 |
| Cook, AJMC | 1 |
| Liens, A | 1 |
| Stoica, M | 1 |
| Ignatyev, K | 1 |
| Street, SR | 1 |
| Wu, J | 1 |
| Chiu, YL | 1 |
| Davenport, AJ | 1 |
| Qiu, Z | 1 |
| Shu, J | 1 |
| Tang, D | 1 |
| Gao, X | 1 |
| Zhang, J | 3 |
| Huang, K | 1 |
| Wai, H | 1 |
| Du, K | 1 |
| Anesini, J | 1 |
| Kim, WS | 1 |
| Eastman, A | 1 |
| Micalizio, GC | 1 |
| Liang, JH | 1 |
| Huo, XK | 1 |
| Cheng, ZB | 1 |
| Sun, CP | 1 |
| Zhao, JC | 1 |
| Kang, XH | 1 |
| Zhang, TY | 1 |
| Chen, ZJ | 1 |
| Yang, TM | 1 |
| Wu, YY | 1 |
| Deng, XP | 1 |
| Zhang, YX | 1 |
| Salem, HF | 1 |
| Kharshoum, RM | 1 |
| Abou-Taleb, HA | 1 |
| AbouTaleb, HA | 1 |
| AbouElhassan, KM | 1 |
| Ohata, C | 1 |
| Ohyama, B | 1 |
| Kuwahara, F | 1 |
| Katayama, E | 1 |
| Nakama, T | 1 |
| Kobayashi, S | 1 |
| Kashiwagi, T | 1 |
| Kimura, J | 1 |
| Lin, JD | 1 |
| Liou, MJ | 1 |
| Hsu, HL | 1 |
| Leong, KK | 1 |
| Chen, YT | 1 |
| Wang, YR | 1 |
| Hung, WS | 1 |
| Lee, HY | 1 |
| Tsai, HJ | 1 |
| Tseng, CP | 1 |
| Alten, B | 1 |
| Yesiltepe, M | 1 |
| Bayraktar, E | 1 |
| Tas, ST | 1 |
| Gocmen, AY | 1 |
| Kursungoz, C | 1 |
| Martinez, A | 1 |
| Sara, Y | 1 |
| Huang, S | 2 |
| Adams, E | 1 |
| Van Schepdael, A | 1 |
| Wang, Q | 1 |
| Chung, CY | 1 |
| Yang, W | 1 |
| Yang, G | 1 |
| Chough, S | 1 |
| Chen, Y | 1 |
| Yin, B | 1 |
| Bhattacharya, R | 1 |
| Hu, Y | 1 |
| Saeui, CT | 1 |
| Yarema, KJ | 1 |
| Betenbaugh, MJ | 1 |
| Zhang, H | 2 |
| Patik, JC | 1 |
| Tucker, WJ | 1 |
| Curtis, BM | 1 |
| Nelson, MD | 1 |
| Nasirian, A | 1 |
| Park, S | 1 |
| Brothers, RM | 1 |
| Dohlmann, TL | 1 |
| Hindsø, M | 1 |
| Dela, F | 1 |
| Helge, JW | 1 |
| Larsen, S | 1 |
| Gayani, B | 1 |
| Dilhari, A | 1 |
| Wijesinghe, GK | 1 |
| Kumarage, S | 1 |
| Abayaweera, G | 1 |
| Samarakoon, SR | 1 |
| Perera, IC | 1 |
| Kottegoda, N | 1 |
| Weerasekera, MM | 1 |
| Nardi, MV | 1 |
| Timpel, M | 1 |
| Ligorio, G | 1 |
| Zorn Morales, N | 1 |
| Chiappini, A | 1 |
| Toccoli, T | 1 |
| Verucchi, R | 1 |
| Ceccato, R | 1 |
| Pasquali, L | 1 |
| List-Kratochvil, EJW | 1 |
| Quaranta, A | 1 |
| Dirè, S | 1 |
| Heo, K | 1 |
| Jo, SH | 1 |
| Shim, J | 1 |
| Kang, DH | 1 |
| Kim, JH | 1 |
| Park, JH | 1 |
| Akhtar, N | 1 |
| Saha, A | 1 |
| Kumar, V | 1 |
| Pradhan, N | 1 |
| Panda, S | 1 |
| Morla, S | 1 |
| Kumar, S | 1 |
| Manna, D | 1 |
| Wang, H | 1 |
| Xu, E | 1 |
| Yu, S | 1 |
| Li, D | 1 |
| Quan, J | 1 |
| Xu, L | 1 |
| Saslow, SA | 1 |
| Um, W | 1 |
| Pearce, CI | 1 |
| Bowden, ME | 1 |
| Engelhard, MH | 1 |
| Lukens, WL | 1 |
| Kim, DS | 1 |
| Schweiger, MJ | 1 |
| Kruger, AA | 1 |
| Adair, LS | 1 |
| Kuzawa, C | 1 |
| McDade, T | 1 |
| Carba, DB | 1 |
| Borja, JB | 1 |
| Liang, X | 2 |
| Song, W | 1 |
| Wang, K | 1 |
| Zhang, B | 1 |
| Peele, ME | 1 |
| Luo, HR | 1 |
| Chen, ZY | 1 |
| Fei, JJ | 1 |
| Du, ZJ | 1 |
| Yi, KJ | 1 |
| Im, WT | 1 |
| Kim, DW | 1 |
| Ji, X | 1 |
| Zhang, C | 1 |
| Xu, Z | 1 |
| Ding, Y | 1 |
| Song, Q | 1 |
| Li, B | 2 |
| Zhao, H | 1 |
| Lee, DW | 1 |
| Lee, H | 1 |
| Kwon, BO | 1 |
| Khim, JS | 1 |
| Yim, UH | 1 |
| Park, H | 1 |
| Park, B | 1 |
| Choi, IG | 1 |
| Kim, BS | 1 |
| Kim, JJ | 1 |
| Wang, JJ | 1 |
| Chen, Q | 1 |
| Li, YZ | 1 |
| Sakai, M | 1 |
| Yamaguchi, M | 1 |
| Nagao, Y | 1 |
| Kawachi, N | 1 |
| Kikuchi, M | 1 |
| Torikai, K | 1 |
| Kamiya, T | 1 |
| Takeda, S | 1 |
| Watanabe, S | 1 |
| Takahashi, T | 1 |
| Arakawa, K | 1 |
| Nakano, T | 1 |
| Rufo, S | 1 |
| Continentino, MA | 1 |
| Nikolaou, V | 1 |
| Plass, F | 1 |
| Planchat, A | 1 |
| Charisiadis, A | 1 |
| Charalambidis, G | 1 |
| Angaridis, PA | 1 |
| Kahnt, A | 1 |
| Odobel, F | 1 |
| Coutsolelos, AG | 1 |
| Fuentes, I | 1 |
| García-Mendiola, T | 1 |
| Sato, S | 1 |
| Pita, M | 1 |
| Nakamura, H | 1 |
| Lorenzo, E | 1 |
| Teixidor, F | 1 |
| Marques, F | 1 |
| Viñas, C | 1 |
| Liu, F | 1 |
| Qi, P | 1 |
| Zhang, L | 1 |
| Torres, PJ | 1 |
| Ho, BS | 1 |
| Arroyo, P | 1 |
| Sau, L | 1 |
| Chen, A | 1 |
| Kelley, ST | 1 |
| Thackray, VG | 1 |
| Oduola, OO | 1 |
| Ryan, GA | 1 |
| Umana, E | 1 |
| Conway, U | 1 |
| Purandare, N | 1 |
| Fauser, BC | 2 |
| Wang, HY | 1 |
| Zheng, PS | 1 |
| Tannus, S | 1 |
| Burke, YZ | 1 |
| Kol, S | 1 |
| Birch Petersen, K | 1 |
| Pedersen, NG | 1 |
| Pedersen, AT | 1 |
| Lauritsen, MP | 1 |
| la Cour Freiesleben, N | 1 |
| Balen, AH | 1 |
| Morley, LC | 1 |
| Misso, M | 1 |
| Franks, S | 1 |
| Legro, RS | 3 |
| Wijeyaratne, CN | 1 |
| Stener-Victorin, E | 1 |
| Norman, RJ | 2 |
| Teede, H | 1 |
| Wang, R | 1 |
| Kim, BV | 1 |
| van Wely, M | 1 |
| Johnson, NP | 1 |
| Costello, MF | 1 |
| Ng, EH | 1 |
| Bhattacharya, S | 1 |
| Mol, BW | 1 |
| Badawy, A | 1 |
| Mosbah, A | 1 |
| Tharwat, A | 1 |
| Eid, M | 1 |
| Pritts, EA | 1 |
| Abdellah, MS | 1 |
| Kamath, MS | 1 |
| George, K | 1 |
| Casper, RF | 2 |
| Mitwally, MF | 2 |
| Propst, AM | 1 |
| Bates, GW | 1 |
| Bayar, U | 1 |
| Tanriverdi, HA | 1 |
| Barut, A | 1 |
| Ayoğlu, F | 1 |
| Ozcan, O | 1 |
| Kaya, E | 1 |
| Rowe, T | 1 |
| Nader, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial[NCT02703649] | Phase 4 | 36 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Laparoscopic Ovarian Drilling Versus Letrozole In Clomiphene Citrate Resistant Polycystic Ovary: A Randomized Controlled Trial[NCT03664050] | Phase 3 | 90 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| Efficacy of Combined Letrozole-metformin in Comparison With Letrozole Only in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome[NCT03135301] | Phase 3 | 80 participants (Anticipated) | Interventional | 2017-06-20 | Recruiting | ||
| Dosage Optimization for Letrozole Treatment in Clomiphene Resistant Patients With Polycystic Ovary Syndrome: A Prospective Interventional Study[NCT01315912] | Phase 4 | 44 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Multicenter Randomized Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth for Infertility in Women With Polycystic Ovary Syndrome[NCT03625531] | Phase 3 | 1,100 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | ||
| Intrauterine Insemination With Letrozole Versus Intrauterine Insemination in Natural Cycle. A Randomised Controlled Trial[NCT03455426] | 100 participants (Actual) | Interventional | 2018-03-15 | Completed | |||
| Letrozole Versus Laparoscopic Ovarian Drilling for Clomiphene-resistant Women With Polycystic Ovary Syndrome[NCT03009838] | Phase 3 | 150 participants (Anticipated) | Interventional | 2017-01-02 | Recruiting | ||
| Follicular Synchronization in Polycystic Ovarian Syndrome Patients Undergoing Intracytoplasmatic Sperm Injection With Letrozole /Antagonist Protocol: A Randomized Controlled Trial[NCT04069117] | Phase 4 | 200 participants (Actual) | Interventional | 2019-08-01 | Completed | ||
| Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET. A Randomized Controlled Trial[NCT04268927] | Phase 2 | 106 participants (Anticipated) | Interventional | 2018-04-01 | Recruiting | ||
| Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Patients With Poor Ovarian Response Undergoing IVF-ET, a Randomized Controlled Trial[NCT01219153] | Phase 2 | 136 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination[NCT01232075] | Phase 2 | 214 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Use of High Cost Monitoring During Letrozole Ovulation Induction and Effect on Pregnancy Rates - A Pilot Study[NCT01279200] | Phase 4 | 21 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Clomiphene Citrate Plus HPuFSH Versus Letrozole Plus HPuFSH in Clomid Resistant Infertile PCOS Women[NCT01793038] | 160 participants (Anticipated) | Interventional | 2013-03-31 | Recruiting | |||
| Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer in Polycystic Ovary Syndrome (PCOS) Patients[NCT02775877] | 100 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | |||
| Comparison Between the Role of Follicular Output Rate and Preovulatory Count in the Prediction of Pregnancy in Women With Polycystic Ovarian Syndrome Undergoing Intra Cytoplasmic Sperm Injection (ICSI)[NCT02190006] | 300 participants (Anticipated) | Observational | 2014-07-31 | Recruiting | |||
| Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome[NCT00427700] | Phase 3 | 82 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of women in each arm who became pregnant within the study time frame. (NCT01279200)
Timeframe: 3 menstrual/treatment cycles (approximately 28-33 days each)
| Intervention | percentage of participants (Number) |
|---|---|
| Urinary LH Kits | 75 |
| Midcycle Ultrasound + hCG Injection | 25 |
Cycles means treatment/menstrual cycles, approximately 28-33 days. (NCT01279200)
Timeframe: 3 menstrual/treatment cycles, or upon conception, whichever comes first
| Intervention | menstrual cycles (Mean) |
|---|---|
| Urinary LH Kits | 1.83 |
| Midcycle Ultrasound + hCG Injection | 1 |
Ovulation detected by ultrasound was defined as the percentage of a participants with ovulation detected by ultrasound, defined as the dominant follicle and its subsequent collapse. If a dominant follicle was not observed by day 21 after menses, the ovulation induction was considered to be a failure. (NCT00427700)
Timeframe: cycle day 14-20
| Intervention | percentage of participants (Number) |
|---|---|
| Clomiphene | 52.5 |
| Raloxifene | 40.4 |
The level of serum progesterone that indicated ovulation was considered to be 3 ng/mL or greater, on days 8 to 10 after ovulation. (NCT00427700)
Timeframe: 8-10 days after ovulation
| Intervention | ng/mL (Mean) |
|---|---|
| Clomiphene | 26.1 |
| Raloxiphene | 40 |
13 reviews available for letrozole and Anovulation
| Article | Year |
|---|---|
Polycystic ovarian syndrome-current pharmacotherapy and clinical implications.
Topics: Acupuncture; Anovulation; Eflornithine; Female; Herbal Medicine; Hirsutism; Humans; Hydroxymethylglu | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2022 |
The future of frozen-thawed embryo transfer in hormone replacement therapy cycles.
Topics: Anovulation; Cryopreservation; Embryo Transfer; Female; Hormone Replacement Therapy; Humans; Letrozo | 2023 |
Topics: Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Letrozole; Male; Semen | 2023 |
Controversial association between polycystic ovary syndrome and breast cancer.
Topics: Androgens; Anovulation; Aromatase Inhibitors; Breast Neoplasms; Clomiphene; Contraceptives, Oral, Co | 2019 |
Treatment strategies for the infertile polycystic ovary syndrome patient.
Topics: Anovulation; Antineoplastic Agents; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, | 2015 |
Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction.
Topics: Adult; Anovulation; Body Weight; Clomiphene; Female; Fertility Agents, Female; Gonadotropins; Humans | 2016 |
The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Consensus; Female; Fertility Agents, Female; Fertiliz | 2016 |
Ovulation induction in polycystic ovary syndrome: Current options.
Topics: Anovulation; Anti-Obesity Agents; Aromatase Inhibitors; Bariatric Surgery; Clomiphene; Diet Therapy; | 2016 |
Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis
Topics: Anovulation; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Female; Letrozole; | 2017 |
Letrozole for ovulation induction and controlled ovarian hyperstimulation.
Topics: Anovulation; Aromatase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2010 |
Evaluation and treatment of anovulatory and unexplained infertility.
Topics: Anovulation; Clomiphene; Diet; Evidence-Based Medicine; Exercise; Female; Fertility Agents, Female; | 2012 |
Ovulation induction in polycystic ovary syndrome.
Topics: Adult; Anovulation; Aromatase Inhibitors; Body Mass Index; Clomiphene; Diathermy; Female; Fertility | 2008 |
5 trials available for letrozole and Anovulation
| Article | Year |
|---|---|
Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp | 2018 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Reproductive outcome after letrozole versus laparoscopic ovarian drilling for clomiphene-resistant polycystic ovary syndrome.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Administration Schedule; Drug Resistance; | 2011 |
Letrozole vs. clomiphene citrate in patients with ovulatory infertility.
Topics: Administration, Oral; Adult; Anovulation; Clomiphene; Endometriosis; Female; Fertility Agents, Femal | 2006 |
Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate.
Topics: Anovulation; Aromatase Inhibitors; Chorionic Gonadotropin; Endometrium; Enzyme Inhibitors; Estradiol | 2001 |
10 other studies available for letrozole and Anovulation
| Article | Year |
|---|---|
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; | 2022 |
Suppression of neurotransmission on gonadotropin-releasing hormone neurons in letrozole-induced polycystic ovary syndrome: A mouse model.
Topics: Animals; Anovulation; Female; Gonadotropin-Releasing Hormone; Humans; Letrozole; Mice; Neurons; Neur | 2022 |
Influence of the conclusion of a recent large cooperative study in changing standard protocol of inducing menses in anovulatory women with oligomenorrhea prior to initiating ovulation induction with anti-estrogens and outcome.
Topics: Adult; Anovulation; Clomiphene; Endometrium; Estrogen Antagonists; Estrogens; Female; Fertility Agen | 2017 |
Exposure to a Healthy Gut Microbiome Protects Against Reproductive and Metabolic Dysregulation in a PCOS Mouse Model.
Topics: Animals; Anovulation; Aromatase Inhibitors; Disease Models, Animal; Dysbiosis; Female; Gastrointesti | 2019 |
Ovulation induction: comparing success rates between anovulatory and ovulatory cycles using different treatment protocols.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Follicle Stimulating Hormone; Humans; | 2019 |
Reproductive endocrinology: revisiting ovulation induction in PCOS.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility | 2014 |
A comparison of the efficacy of two doses of letrozole alone or with continuous recombinant follicle-stimulating hormone for ovulation induction in anovulatory women.
Topics: Adult; Anovulation; Aromatase Inhibitors; Drug Therapy, Combination; Female; Follicle Stimulating Ho | 2015 |
Letrozole or clomiphene citrate as first line for anovulatory infertility: a debate.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Hu | 2011 |
Letrozole or clomiphene citrate as first line for anovulatory infertility: a debate.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Hu | 2011 |
Letrozole or clomiphene citrate as first line for anovulatory infertility: a debate.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Hu | 2011 |
Letrozole or clomiphene citrate as first line for anovulatory infertility: a debate.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Hu | 2011 |
Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Congenital Abnormalities; Female; Fertility Agents, F | 2011 |
Clomiphene citrate: an old favourite lives on.
Topics: Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Letrozole; N | 2007 |